Alport syndrome

Also found in: Encyclopedia, Wikipedia.

Alport Syndrome



A hereditary disease of the kidneys that primarily affects men, causing blood in the urine, hearing loss and eye problems. Eventually, kidney dialysis or transplant may be necessary.


Alport syndrome affects about one in 5,000 Americans, striking men more often and severely than women. There are several varieties of the syndrome, some occurring in childhood and others not causing symptoms until men reach their 20s or 30s. All varieties of the syndrome are characterized by kidney disease that usually progresses to chronic kidney failure and by uremia (the presence of excessive amounts of urea and other waste products in the blood).

Causes and symptoms

Alport syndrome in most cases is caused by a defect in one or more genes located on the X chromosome. It is usually inherited from the mother, who is a normal carrier. However, in up to 20% of cases there is no family history of the disorder. In these cases, there appears to be a spontaneous genetic mutation causing Alport syndrome.
Blood in the urine (hematuria) is a hallmark of Alport syndrome. Other symptoms that may appear in varying combinations include:
  • protein in the urine (proteinuria)
  • sensorineural hearing loss
  • eye problems [involuntary, rhythmic eye movements (nystagmus), cataracts, or cornea problems]
  • skin problems
  • platelet disorders
  • abnormal white blood cells
  • smooth muscle tumors
Not all patients with Alport syndrome have hearing problems. In general, those with normal hearing have less severe cases of Alport syndrome.


Alport syndrome is diagnosed with a medical evaluation and family history, together with a kidney biopsy that can detect changes in the kidney typical of the condition. Urinalysis may reveal blood or protein in the urine. Blood tests can reveal a low platelet level.
In addition, tests for the Alport gene are now available. Although testing is fairly expensive, it is covered by many types of health insurance. DNA tests can diagnose affected children even before birth, and genetic linkage tests tracing all family members at risk for Alport syndrome are also available.


There is no specific treatment that can "cure" Alport syndrome. Instead, care is aimed at easing the problems related to kidney failure, such as the presence of too many waste products in the blood (uremia).
To control kidney inflammation (nephritis), patients should:
  • restrict fluids
  • control high blood pressure
  • manage pulmonary edema
  • control high blood levels of potassium
Rarely patients with Alport syndrome may develop nephrotic syndrome, a group of symptoms including too much protein in the urine, low albumin levels, and swelling. To ease these symptoms, patients should:
  • drink less
  • eat a salt-free diet
  • use diuretics
  • have albumin transfusions
The treatment for chronic kidney failure is dialysis or a kidney transplant.


Women with this condition can lead a normal life, although they may have slight hearing loss. An affected woman may notice blood in her urine only when under stress or pregnant.
Men generally have a much more serious problem with the disease. Most will experience kidney disease in their 20s or 30s, which may eventually require dialysis or transplantation, and many develop significant hearing loss. Men with Alport syndrome often die of complications by middle age.


Alport syndrome is a genetic disease and prevention efforts are aimed at providing affected individuals and their families with information concerning the genetic mechanisms responsible for the disease. Since it is possible to determine if a woman is a carrier, or if an unborn child has the condition, genetic counseling can provide helpful information and support for the decisions that affected individuals and their families may have to make.

Key terms

Albumin — A protein that is important in maintaining blood volume. Low albumin levels is one sign of Alport syndrome.
Dialysis — A technique of removing waste material from the blood. It is used with patients whose kidneys have stopped functioning and can no longer cleanse the blood on their own.
Diuretic — A drug that increases the amount of urine a person produces.
Hematuria — Blood in the urine, Hematuria is a hallmark of Alport syndrome.
Pulmonary edema — Excess fluid in the air spaces of the lungs.
Uremia — The presence of excessive amounts of urea and other waste products in the blood.



American Association of Kidney Patients. 100 S. Ashley Dr., #280, Tampa, FL 33602. (800) 749-2257.
American Kidney Fund (AKF). Suite 1010, 6110 Executive Boulevard, Rockville, MD 20852. (800) 638-8299.
National Kidney and Urologic Disease Information Clearinghouse. 3 Information Way, Bethesda, MD 20892. (301) 654-4415.
National Kidney Foundation. 30 East 33rd St., New York, NY 10016. (800) 622-9010.
National Organization for Rare Diseases. P.O. Box 8923, Fairfield, CT 06812. (213) 745-6518. 〈〉.


Alport Syndrome Home Page. 〈∼cla6202/ASHP.htm〉.
"Alport Syndrome." Pediatric Database Home Page. 〈〉.
The Hereditary Nephritis Foundation (HNF) Home Page. 〈∼cla6202/HNF.htm〉.

Al·port syn·drome

a genetically heterogeneous disorder characterized by nephritis associated with microscopic hematuria and slow progression of renal failure, sensorineural hearing loss, and ocular abnormalities such as lenticonus and maculopathy; autosomal dominant [MIM*104200, MIM*153640, and MIM*153650], autosomal recessive [MIM*203780], and X-linked recessive [MIM*301050 and MIM*303630] forms exist. The X-linked form is caused by mutation in the collagen type IV α-5 gene (COL4A5) on chromosome Xq; the autosomal recessive form results from mutation in the collagen type IV α-3 gene (COL4A3) or α-4 gene (COL4A4) on 2q.

Alport syndrome

A heterogeneous group of conditions with variable patterns of heredity–most are X-R but also AD and AR frequency 1 in 50,000 Clinical Glomerulonephritis, hematuria, proteinuria, evolving to HTN, nephrotic syndrome, and end-stage renal disease, variably accompanied by sensorineural deafness, colored urine, swelling, cough, poor vision Treatment Kidney transplant may be successful in absence of anti-glomerular basement membrane and anti-tubular antibodies

Al·port syn·drome

(al'pōrt sin'drōm)
A genetically heterogeneous disorder characterized by nephritis associated with microscopic hematuria and slowly progressive renal failure, sensorineural hearing loss, and ocular abnormalities such as lenticonus and maculopathy; autosomal dominant, autosomal recessive, and X-linked recessive forms exist. The X-linked form is caused by mutation in the collagen type IV alpha-5 gene (COL4A5) on chromosome Xq; the autosomal recessive form is due to mutation in the collagen type IV alpha-3 gene (COL4A3) or alpha-4 gene (COL4A4) on 2q.


Arthur Cecil, South African physician, 1880-1959.
Alport syndrome - progressive microscopic hematuria.
References in periodicals archive ?
We expect that the results from this first-in-human clinical study of RG-012, combined with our learnings from our natural history of disease study called ATHENA, will provide the clinical basis for the design of a proof-of-concept study to monitor the therapeutic effect of RG-012 in Alport syndrome patients.
In the near term, we expect to initiate our first-in-human clinical study of RG-012, our anti-miR-21 for the treatment of Alport syndrome, and we are aggressively pursuing additional attractive microRNA targets to expand our leadership in the field.
Specifically, we are preparing to initiate Phase II studies for RG-101 and our first clinical study for RG-012, an anti-miR-21 to treat Alport syndrome, and we intend to advance additional programs into clinical development.
A monoclonal antibody marker for Alport syndrome identifies the Alport antigen as the [Alpha]5 chain of type IV collagen.
is a clinical stage biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 to catalyze cartilage regeneration for disease modification of Osteoarthritis (OA) and the inhibition and reversal of organ fibrosis in diseases such as Chronic Kidney Disease (CKD) and Alport Syndrome.
RG-012 is being developed by Regulus in a strategic alliance with Genzyme, a Sanofi company, for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
The researcher sees the application of this approach to collagen-based diseases as a starting point that could lead to a similar analysis of the mechanical properties of tissue involved in other protein-based diseases, including kidney disease Alport syndrome, Ehlers-Danlos syndrome that is characterised by overly-flexible skin and joints, and even Alzheimer's disease.
Dawn said she was found to be suffering from Alport Syndrome, which causes kidney failure, when she was carrying Gary.
Under its 'Clinical Map Initiative', Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy.
A hereditary condition called Alport Syndrome affected the brothers in their early 20s, eventually leading to kidney failure.
These children born with multiple abnormalities may be suffering from one of the named syndromes eg Alport Syndrome, Pendred Syndrome, etc.
A 23-year-old female with chronic renal failure because of Alport syndrome (AS) consulted for cardiac evaluation before renal transplantation.